US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.30 against a street estimate of -0.19 — a beat of 257.9%.
Analysts rate Anika Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $23.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.83% |
| Caligan Partners LP | 10.72% |
| Morgan Stanley - Brokerage Accounts | 4.59% |
| Acadian Asset Management LLC | 4.53% |
| Vanguard Capital Management, LLC | 4.27% |
| AQR Capital Management LLC | 4.18% |
| BOOTHBAY FUND MANAGEMENT, LLC | 3.96% |
| Renaissance Technologies Corp | 3.60% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anika Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.